Synthesis of 4'-Substituted Carbocyclic Uracil Derivatives and Their Monophosphate Prodrugs as Potential Antiviral Agents. 2023

Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
Laboratory of Biochemical Pharmacology, Center for ViroScience and Cure, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.

Over the past decades, both 4'-modified nucleoside and carbocyclic nucleoside analogs have been under the spotlight as several compounds from either family showed anti-HIV, HCV, RSV or SARS-CoV-2 activity. Herein, we designed compounds combining these two features and report the synthesis of a series of novel 4'-substituted carbocyclic uracil derivatives along with their corresponding monophosphate prodrugs. These compounds were successfully prepared in 19 to 22 steps from the commercially available (-)-Vince lactam and were evaluated against a panel of RNA viruses including SARS-CoV-2, influenza A/B viruses and norovirus.

UI MeSH Term Description Entries
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D018937 Hepatitis C Antibodies Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins. Anti-HCV Antibodies,Anti-Hepatitis C Virus Antibodies,HCV Antibodies,Hepatitis C Virus Antibodies,Anti HCV Antibodies,Anti Hepatitis C Virus Antibodies

Related Publications

Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
March 1979, Journal of medicinal chemistry,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
January 2001, Nucleic acids research. Supplement (2001),
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
February 1983, Journal of medicinal chemistry,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
December 2003, Archives of pharmacal research,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
August 2004, Archiv der Pharmazie,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
September 1997, Bollettino chimico farmaceutico,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
November 2004, Archiv der Pharmazie,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
February 2006, Journal of medicinal chemistry,
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
January 2008, Nucleic acids symposium series (2004),
Nicolas G Biteau, and Sarah A Amichai, and Niloufar Azadi, and Ramyani De, and Jessica Downs-Bowen, and Julia C Lecher, and Tamara MacBrayer, and Raymond F Schinazi, and Franck Amblard
January 2020, Acta naturae,
Copied contents to your clipboard!